Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2, Multi-Center, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of the Combination Regimen Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

NCT04653246 is registered in ClinicalTrials.gov with Jacob Laubach, MD as lead sponsor.

NCT NCT04653246
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04653246 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2, Multi-Center, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of the Combination Regimen Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
Lead sponsor
Jacob Laubach, MD
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 13, 2021
Completion date
January 13, 2029
Enrollment
52 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

autologous stem cell transplant, multiple myeloma, newly diagnosed multiple myeloma (ndmm)